Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-16
2011-08-16
Stoica, Elly-Gerald (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S006900, C514S021400, C530S325000
Reexamination Certificate
active
07998928
ABSTRACT:
The present invention is based on the discovery that Humanin and humanin analogues protect pancreatic beta cells in vitro and in vivo from apoptosis. Accordingly, humanin and its analogues are useful for preventing and treating diabetes and promoting beta cell survival in a number of applications.
REFERENCES:
patent: 2006/0246047 (2006-11-01), Imoto et al.
patent: 2008/0039393 (2008-02-01), Mascarenhas
Yechoor et al. Gene therapy for diabetes mellitus, Gene Therapy, 12, 101-107, 2005.
Wang et al. Maintenance of beta cell function and survival following islet isolation requires re-establishment of islet-matrix relationship, J. Endocrinol. 163, 181-190, 1999.
Kim et al., Rosiglitazone protects the pancreatic b-cell death induced by cyclosporine A. Biochem. Biophys. Res. Commun., 390, 763-768, 2009.
Luciano et al. Cytoprotective Peptide Humanin Binds and Inhibits Proapoptotic Bcl-2/Bax Family Protein BimEL. J. Biol. Chem. 280, 15825-15835, 2005.
Arata, M. et al., “Effect of Modified Diabetic Splenocytes on Mice Injected with Splenocytes from Multiple Low-Dose Streptozotocin Diabetic Donors,”Exp. Biol. Med., 2001, vol. 226, No. 10, pp. 898-905.
Chiba, T. et al., “Development of a Femtomolar-Acting Humanin Derivative Named Colivelin by Attaching Activity-Dependent Neurotrophic Factor to Its N Terminus: Characterization of Coliveline-Mediated Neuroprotection against Alzheimer's Disease-Relevant Insults In Vitro and In Vivo,”The Journal of Neuroscience, Nov. 2, 2005, vol. 25, No. 44, pp. 10252-10261.
Cobb, L. et al., “Site-Specific Phosphorylation by Intracellular Kinases Determines the Apoptotic Activity of IGFBP-3,”Growth Hormone&IGF Research, Abstracts, 3rdInt. Congress of GRS & IGF Society, 2006, Abstract No. OR04-6, p. S8.
Cobb, L.J. et al., “Phosphorylation of Ser-156 by DNA-PK is Functionally Critical for Apoptosis Induction by IGFBP-3,”The Endocrine Society Program&Abstracts, 88thAnnual Meeting, Jun. 24-27, 2006, Boston, MA, Abstract No. P1-201, 2 pages.
Eisenbarth, G.S., “Update, Update in Type 1 Diabetes,”The Journal of Clinical Endocrinology&Metabolism, 2007, vol. 92, No. 7, pp. 2403-2407.
Eizirik, D.L. et al., “A choice of death—the signal-tramsduction of immune-mediated beta- cell apoptosis,”Diabetologica, 2001, vol. 44, pp. 2115-2133.
Guo, B. et al., “BcI-G, a Novel Pro-apoptotic Member of the Bcl-2 Family,”The Journal of Biological Chemistry, Jan. 26, 2001, vol. 276, No. 4, pp. 2780-2785.
Guo, B. et al., “Humanin peptide suppresses apoptosis by interfacing with Bax activation,”Nature, May 23, 2003, vol. 423, pp. 456-461.
Hashimoto, Y. et al, “A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ, ”PNAS, May 22, 2001, vol. 98, No. 11, pp. 6336-6341.
Ikonen, M. et al., “Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis,”PNAS, Oct. 28, 2003, vol. 100, No. 22, pp. 13042-13047.
Iribarren, P. et al., “Role of Formlyl Peptide Receptor-Like 1(FPRL1/FPR2) in Mononuclear Phagocyte Responses in Alzheimer Disease,”Immunologic Research, 2005, vol. 31, pp. 165-176.
Jiang, J. et al., “Generation of Insulin-Producing Islet-Like Clusters from Human Embryonic Stem Cells,”Stem Cells, 2007, vol. 25, pp. 1940-1953.
Kayali, A.G. et al., “Limited Capacity of Human Adult Islets Expanded in Vitro to Redifferentiate Into Insulin-Producing β-Cells,”Diabetes, Mar. 2007, vol. 56, pp. 703-708.
King, A.J.F. et al., “Normal Relationship of β- and Non-β-Cells not Needed for Successful Islet Transplantation,”Diabetes, Sep. 2007, vol. 56, pp. 2312-2318.
Lee, K-W. et al., “The IGFBP-3 Partner, Humanin, Protects Beta Cells From Apoptosis in Vitro and Improves Glucose Tolerance in the Nod Model in Vivo,”Growth Hormone&IGF Research, Abstracts, 3rdInt. Congress of GRS & IGF Society, 2006, vol. 16, Suppl B, Oral presentations: Nov. 13, 2006, Abstract No. OR08-4, pp. S15-S16.
Lehmann, R. et al., “Superiority of Small Islets in Human Islet Transplantation,”Diabetes, Mar. 2007, vol. 56, pp. 594-603.
Nishimoto, I. et al., “Unravelling the role of Humanin,”TRENDS in Molecular Medicine, Mar. 2004, vol. 10, No. 3, pp. 102-105.
O'Brien, B.A. et al., “Apoptosis is the Mode of β-Cell Death Responsible for the Development of IDDM in the Nonobese Diabetic (NOD) Mouse,”Diabetes, May 1997, vol. 46, pp. 750-757.
Paraskevas, S. et al., “Activation and expression of ERK, JNK, and p38 MAP-kinases in isolated islets of Langerhans: implications for cultured islet survival,”FEBS Letters, 1999, vol. 455, pp. 203-208.
Park, P. et al., “The Neuro-Survival Peptide, Humanin, Protects β Cells from Apoptosis In Vitro and Improves Glucose Tolerance in the NOD Model In Vivo,”The Endocrine Society Program&Abstracts, 88thAnnual Meeting, Jun. 24-27, 2006, Boston, MA, Abstract No. OR26-2, p. 110.
Parkash, J. et al., “Tumor Necrosis Factor-α-Induced Changes in Insulin-Producing β- Cells,”The Anatomical Record Part A, 2005, vol. 286A, pp. 982-993.
Rajah, R. et al., “Insulin-like Growth Factor (IGF)-binding Protein-3 Induces Apoptosis and Mediates the Effects of Transforming Growth Factor-β1 on Programmed Cell Death through a p53- and IGF-independent Mechanism,”The Journal of Biological Chemistry, May 2, 1997, vol. 272, No. 18, pp. 12181-12188.
Shim, M.L. et al., “Insulin-like growth factor binding protein-3 is a novel mediator of apoptosis in insulin-secreting cells,”Growth Hormone IGF Research, 2004, vol. 14, pp. 216-225.
Stephens, L.A. et al., “Tumor Necrosis Factor-α-Activated Cell Death Pathways in NIT-1 Insulinoma Cells and Primary Pancreatic β Cells,”Endocrinology, 1999, vol. 140, No. 7, pp. 3219-3227.
Thomas, D. et al., “Proapoptotic Bax is Hyperexpressed in Isolated Human Islets Compared With Antiapoptotic BCL-2,”Transplantation, Dec. 15, 2002, vol. 74, No. 11, pp. 1489-1490.
Tobiasch, E. et al., “Herne Oxygenase-1 Protects Pancreatic β Cells From Apoptosis Caused by Various Stimuli,”Journal of Investigation Medicine, Nov. 2001, vol. 49, No. 6, pp. 566-571.
Yatoh, S. et al., “Differentiation of Affinity-Purified Human Pancreatic Duct Cells to β-Cells,”Diabetes, Jul. 2007, vol. 56, pp. 1802-1809.
Cohen Pinchas
Lee Kuk-Wha
Morgan & Lewis & Bockius, LLP
Parent Annette S.
Stoica Elly-Gerald
The Regents of the University of California
LandOfFree
Method of treatment of type-1 diabetes with a humanin analogue does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment of type-1 diabetes with a humanin analogue, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment of type-1 diabetes with a humanin analogue will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2690939